EpiGeneer’s Post

Innovation in Alzheimer’s research starts with rethinking how we use data.   IGC Pharma’s AI-driven platform, AHA: Agentic Harmonization Assistant, has been recognized on the global stage—advancing to the semi-finals of the Alzheimer’s Insights AI Prize organized by the Alzheimer's Disease Data Initiative   By building on the foundation of MINT-AD, our deep-learning platform that unites complex clinical and biological information, we’re pushing the boundaries of what’s possible in Alzheimer’s drug discovery.   For more information, please visit: https://bit.ly/47D7n9C #AlzheimersResearch #AIinHealthcare #HealthcareInnovation #Neuroscience #IGCPharma

📢 Nexalin Technology: Breakthrough in Alzheimer’s Treatment 🧠 Millions face the growing challenge of Alzheimer’s, and Nexalin is changing the treatment paradigm. Nexalin Technology (Nasdaq: NXL) recently announced peer-reviewed results showing its patented Deep Intracranial Frequency Stimulation (DIFS™) technology improved cognitive performance and enhanced brain connectivity in patients with mild Alzheimer’s disease, as published in Radiology. 🎥 Watch our 30-Second Overview: 👉 https://lnkd.in/ehZXszM4 University of Pennsylvania School of Medicine UC San Diego School of Medicine PharmaVoice Genetic Engineering & Biotechnology News Biotechnology #NXL #BiotechStocks #Alzheimers #Neurostimulation #MentalHealth #HealthcareInnovation #Investing #FinancialNews

📢 Nexalin Technology: Breakthrough in Alzheimer’s Treatment 🧠 Millions face the growing challenge of Alzheimer’s, and Nexalin is changing the treatment paradigm. Nexalin Technology (Nasdaq: NXL) recently announced peer-reviewed results showing its patented Deep Intracranial Frequency Stimulation (DIFS™) technology improved cognitive performance and enhanced brain connectivity in patients with mild Alzheimer’s disease, as published in Radiology. 🎥 Watch our 30-Second Overview: 👉 https://lnkd.in/ehZXszM4 University of Pennsylvania School of Medicine UC San Diego School of Medicine PharmaVoice Genetic Engineering & Biotechnology News Biotechnology #NXL #BiotechStocks #Alzheimers #Neurostimulation #MentalHealth #HealthcareInnovation #Investing #FinancialNews

𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐢𝐧 𝐒𝐩𝐢𝐧𝐚𝐥 𝐂𝐨𝐫𝐝 𝐈𝐧𝐣𝐮𝐫𝐲 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭: 𝐀 𝐍𝐞𝐰 𝐄𝐫𝐚 𝐨𝐟 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞 𝐭𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/g_ppksvR After 25 years of relentless research, Brazil has introduced the world’s first drug capable of repairing damaged spinal cords — a groundbreaking step forward for neuroscience and regenerative medicine. 🧠🧬 What makes this innovation truly remarkable is not just the drug itself, but the precision of its targeted delivery. Designed to act directly at the site of spinal injury, this approach minimizes systemic side effects while maximizing therapeutic impact — a core principle of next-generation targeted drug delivery devices. 🔍 𝐖𝐡𝐲 𝐭𝐡𝐢𝐬 𝐦𝐚𝐭𝐭𝐞𝐫𝐬 ✅ Enables localized repair of nerve tissue ✅ Reduces the need for invasive surgeries ✅ Offers new hope to millions living with paralysis or chronic spinal injuries ✅ Paves the way for targeted therapies in other neurodegenerative conditions 💡 As targeted delivery platforms continue to evolve, we’re moving closer to treatments that don’t just manage symptoms — they restore function. This milestone is a powerful reminder of how science, persistence, and advanced delivery technologies can change the future of medicine. #TargetedDrugDelivery #Neuroscience #SpinalCordInjury #DrugDevelopment #BiotechInnovation #RegenerativeMedicine #HealthcareBreakthrough #BrazilScience

📚 𝐋𝐚𝐬𝐭 𝐂𝐡𝐚𝐧𝐜𝐞 𝐭𝐨 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝗙𝘂𝗹𝗹 𝐏𝐃𝐅: https://lnkd.in/dSXXyj7v After 25 years of cutting-edge research, 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗼𝗳 𝗦ã𝗼 𝗣𝗮𝘂𝗹𝗼 𝗵𝗮𝘃𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗲𝗱 𝗮 𝗳𝗶𝗿𝘀𝘁-𝗼𝗳-𝗶𝘁𝘀-𝗸𝗶𝗻𝗱 𝗱𝗿𝘂𝗴 𝘁𝗵𝗮𝘁 𝗰𝗮𝗻 𝗿𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗲 𝗱𝗮𝗺𝗮𝗴𝗲𝗱 𝘀𝗽𝗶𝗻𝗮𝗹 𝗰𝗼𝗿𝗱𝘀 — a historic breakthrough that could help millions walk again ✅ 💉 The drug, called FS271, works by repairing nerve pathways and restoring communication between neurons — something once thought impossible in spinal cord injuries. 🐁 In lab tests on mice and primates, paralyzed animals regained movement — proof that the nervous system can heal with the right molecular trigger. 🧠 Human trials are expected soon — and if successful, FS271 could usher in a new era of regenerative medicine for conditions like paralysis, MS, and traumatic nerve damage. 🔬 Behind this miracle? A Brazilian team led by geneticist Dr. Mayana Zatz, and the tireless work of the Human Genome and Stem Cell Research Center in São Paulo. ✨ A cure for paralysis may finally be on the horizon — and it’s coming from Brazil. #BrazilScience #SpinalCordRecovery #MedicalMiracle #Neuroscience #FS271 #StemCellTherapy #HumanTrialsNext #HealthInnovation #RegenerativeMedicine #ParalysisHope #MayanaZatz #USP #ScienceThatHeals #FromLabToLife #AI #ArtificialIntellegence #Healthcare

After 25 years of cutting-edge research, 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗼𝗳 𝗦ã𝗼 𝗣𝗮𝘂𝗹𝗼 𝗵𝗮𝘃𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗲𝗱 𝗮 𝗳𝗶𝗿𝘀𝘁-𝗼𝗳-𝗶𝘁𝘀-𝗸𝗶𝗻𝗱 𝗱𝗿𝘂𝗴 𝘁𝗵𝗮𝘁 𝗰𝗮𝗻 𝗿𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗲 𝗱𝗮𝗺𝗮𝗴𝗲𝗱 𝘀𝗽𝗶𝗻𝗮𝗹 𝗰𝗼𝗿𝗱𝘀 — a historic breakthrough that could help millions walk again ✅ 📚 𝐋𝐚𝐬𝐭 𝐂𝐡𝐚𝐧𝐜𝐞 𝐭𝐨 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝗙𝘂𝗹𝗹 𝐏𝐃𝐅: https://lnkd.in/dSXXyj7v 💉 The drug, called FS271, works by repairing nerve pathways and restoring communication between neurons — something once thought impossible in spinal cord injuries. 🐁 In lab tests on mice and primates, paralyzed animals regained movement — proof that the nervous system can heal with the right molecular trigger. 🧠 Human trials are expected soon — and if successful, FS271 could usher in a new era of regenerative medicine for conditions like paralysis, MS, and traumatic nerve damage. 🔬 Behind this miracle? A Brazilian team led by geneticist Dr. Mayana Zatz, and the tireless work of the Human Genome and Stem Cell Research Center in São Paulo. ✨ A cure for paralysis may finally be on the horizon — and it’s coming from Brazil. #BrazilScience #SpinalCordRecovery #MedicalMiracle #Neuroscience #FS271 #StemCellTherapy #HumanTrialsNext #HealthInnovation #RegenerativeMedicine #ParalysisHope #MayanaZatz #USP #ScienceThatHeals #FromLabToLife #AI #ArtificialIntellegence #Healthcare

After 25 years of cutting-edge research, 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗼𝗳 𝗦ã𝗼 𝗣𝗮𝘂𝗹𝗼 𝗵𝗮𝘃𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗲𝗱 𝗮 𝗳𝗶𝗿𝘀𝘁-𝗼𝗳-𝗶𝘁𝘀-𝗸𝗶𝗻𝗱 𝗱𝗿𝘂𝗴 𝘁𝗵𝗮𝘁 𝗰𝗮𝗻 𝗿𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗲 𝗱𝗮𝗺𝗮𝗴𝗲𝗱 𝘀𝗽𝗶𝗻𝗮𝗹 𝗰𝗼𝗿𝗱𝘀 — a historic breakthrough that could help millions walk again ✅ 📚 𝐋𝐚𝐬𝐭 𝐂𝐡𝐚𝐧𝐜𝐞 𝐭𝐨 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝗙𝘂𝗹𝗹 𝐏𝐃𝐅: https://lnkd.in/dSXXyj7v 💉 The drug, called FS271, works by repairing nerve pathways and restoring communication between neurons — something once thought impossible in spinal cord injuries. 🐁 In lab tests on mice and primates, paralyzed animals regained movement — proof that the nervous system can heal with the right molecular trigger. 🧠 Human trials are expected soon — and if successful, FS271 could usher in a new era of regenerative medicine for conditions like paralysis, MS, and traumatic nerve damage. 🔬 Behind this miracle? A Brazilian team led by geneticist Dr. Mayana Zatz, and the tireless work of the Human Genome and Stem Cell Research Center in São Paulo. ✨ A cure for paralysis may finally be on the horizon — and it’s coming from Brazil. #BrazilScience #SpinalCordRecovery #MedicalMiracle #Neuroscience #FS271 #StemCellTherapy #HumanTrialsNext #HealthInnovation #RegenerativeMedicine #ParalysisHope #MayanaZatz #USP #ScienceThatHeals #FromLabToLife #AI #ArtificialIntellegence #Healthcare

BioVie’s BIV201 Shows Promise in Treating Refractory Ascites! 🚀✨ BioVie Inc. (NASDAQ: BIVI) reports that its innovative therapy BIV201 has demonstrated potential in reducing fluid buildup in refractory ascites by narrowing specific blood vessels, improving blood flow to the kidneys and liver. Watch the latest New to The Street interview here👇🏻👇🏻👇🏻 https://lnkd.in/eCNzk67z Check them out here👇🏻👇🏻👇🏻 bioviepharma.com #bioVie #neuroscience #medical #breakthrough #innovation #businessupdate #businessnews #business #news #newtothestreet

BioVie’s BIV201 Shows Promise in Treating Refractory Ascites! 🚀✨ BioVie Inc. (NASDAQ: BIVI) reports that its innovative therapy BIV201 has demonstrated potential in reducing fluid buildup in refractory ascites by narrowing specific blood vessels, improving blood flow to the kidneys and liver. Watch the latest New to The Street interview here👇🏻👇🏻👇🏻 https://lnkd.in/eUP97vMJ Check them out here👇🏻👇🏻👇🏻 bioviepharma.com #bioVie #neuroscience #medical #breakthrough #innovation #businessupdate #businessnews #business #news #newtothestreet